Limits...
Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication.

Nishizawa T, Suzuki H, Hibi T - J Clin Biochem Nutr (2009)

Bottom Line: Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori.Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs.As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.

ABSTRACT
Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60% to 84%. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs. We recently reported a significant difference in the eradication rate obtained between patients infected with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection of quinolones for third-line therapy should be based on the results of drug susceptibility testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.

No MeSH data available.


Primary resistance of H. pylori to quinolone in different countries.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2654467&req=5

Figure 1: Primary resistance of H. pylori to quinolone in different countries.

Mentions: Primary resistance of H. pylori to quinolones has been reported to range between 2%–22% in different countries or regions [14–21]. The prevalence of quinolone resistance is higher in Japan, Korea and Italy (15–22%), and the prevalence is very low in China and Egypt (about 2%, Fig. 1). We reported ahigh resistance rate (47.9%) togatifloxacin (8-methoxy quinolone) after eradication failure in Japan [22]. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs [23].


Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication.

Nishizawa T, Suzuki H, Hibi T - J Clin Biochem Nutr (2009)

Primary resistance of H. pylori to quinolone in different countries.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2654467&req=5

Figure 1: Primary resistance of H. pylori to quinolone in different countries.
Mentions: Primary resistance of H. pylori to quinolones has been reported to range between 2%–22% in different countries or regions [14–21]. The prevalence of quinolone resistance is higher in Japan, Korea and Italy (15–22%), and the prevalence is very low in China and Egypt (about 2%, Fig. 1). We reported ahigh resistance rate (47.9%) togatifloxacin (8-methoxy quinolone) after eradication failure in Japan [22]. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs [23].

Bottom Line: Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori.Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs.As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.

ABSTRACT
Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60% to 84%. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs. We recently reported a significant difference in the eradication rate obtained between patients infected with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection of quinolones for third-line therapy should be based on the results of drug susceptibility testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.

No MeSH data available.